New immunotherapy IMU-201 tested in advanced lung cancer patients

NCT ID NCT04432207

Terminated Disease control Sponsor: Imugene Limited Source: ClinicalTrials.gov ↗

First seen Mar 26, 2026 · Last updated May 24, 2026 · Updated 8 times

Summary

This early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or with other cancer drugs to see if it is safe and tolerable. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Cabrini Malvern Hospital

Melbourne, Victoria, 3000, Australia
Chris O'Brien Lifehouse

Camperdown, New South Wales, 2050, Australia
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Macquarie University

Macquarie, New South Wales, 2109, Australia
Mayo Clinic

Phoenix, Arizona, 85054, United States
Ohio State University Medical Center

Columbus, Ohio, 43210, United States

Conditions

Explore the condition pages connected to this study.

ADENOCARCINOMA LUNG LARGE CELL CARCINOMA LUNG NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER STAGE IIIB NON-SMALL CELL LUNG CANCER STAGE IIIB NON-SMALL CELL LUNG CANCER STAGE IV NON-SMALL CELL LUNG CANCER STAGE IV SQUAMOUS NON-SMALL-CELL LUNG CANCER